Dr Reddy's recalls cholesterol lowering Atorvastatin tablets in the US

The company initiated a voluntary recall of 2,280 bottles of Atorvastatin Calcium 40 mg 500 tablets on August 2

drugs, generics, drug, pharma, pharmaceuticals, medicines, tablets, capsules, healthcare, IPR
Some major Western concerns about India's patent framework are the definitions of inventions and provisions for compulsory licensing
BS Reporter Hyderabad
Last Updated : Aug 24 2018 | 12:02 AM IST

Dr Reddy's Laboratories Limited has recalled cholesterol lowering Atorvastatin Calcium tablets from the US market after noticing certain anomalies in the out of specifications(OOS) investigations. 

The company initiated a voluntary recall of 2,280 bottles of Atorvastatin Calcium 40 mg 500 tablets on August 2, according to the US Food and Drug Administration(USFDA). This is a class-3 recall, which means the noticed deviations, if exposed to, are unlikely to cause adverse health consequences.   

"Failed impurities/degradation specifications-OOS was observed for ATV cyclo FP impurity and total degradation impurities tested at the 18 month stability time point in Atorvastatin Calcium tablets 40 mg 500 tablets," a notice on the US FDA website said.   

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story